Indian Pharma Market - Covid-19 Boost Sustains In May As Well: Motilal Oswal

Finished tablets cascade down the channels of a packaging machine during the manufacture of the Favipiravir antiviral medicine. (Photographer: Andrey Rudakov/Bloomberg).

Indian Pharma Market - Covid-19 Boost Sustains In May As Well: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Indian pharma market growth was 47.8% YoY in May 2021 versus 51.5% YoY in April 2021.

Strict lockdowns in May 2020 had impacted sales and production (8.9% YoY decline in May 2020).

Anti-Infectives/respiratory/vitamins-minerals-nutrients exhibited a growth of 142%/87%/60% YoY.

In addition to a low base of the past year, anti-Infectives therapies grew sharply in May-21 due to high demand for Covid-19 drugs as well.

Sales momentum in respiratory strengthened further with 87% YoY growth in May-21 (50% YoY growth in April-21).

On a moving annual total basis, industry growth came in at 10.8% YoY.

Click on the attachment to read the full report:

Motilal Oswal Healthcare Sector Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.